After Years Of Partner Search, India's Dr. Reddy's Forms JV With Fujifilm To Tap Japanese Generics Market
This article was originally published in The Pink Sheet Daily
Executive Summary
Although it surprised many in India to have Fujifilm's name associated with generic drugs, its penchant to explore the Japanese market coincides with the Japanese government's mission to encourage use of generic substitutes in Japan to drive costs down.
You may also be interested in...
Dr. Reddy's Labs Saved From Poor India Showing By North America Market Growth, Biosimilars
MUMBAI - Dr. Reddy's Laboratories Ltd. faced an unexpected slowdown in its home market as sales growth in India slipped to just 6% during the first quarter - remarkably lower than the industry average of 14% to 15% - but a 69% rise in sales of its biosimilars products like monoclonal antibody Reditux (rituximab) powered revenues to a respectable $66 million, against $62 million achieved during the same period last year
Teva Buys Japanese Generics Company For $460 Mil.
Teva Pharmaceutical Industries Ltd. announced May 16 that it is acquiring more than half of Japan's third largest generic drugmaker and extending an offer to purchase the remaining portion of the company
Fujifilm Acquires Two Merck Bio Units Looking To Ramp Up Pharma Business
TOKYO - Fujifilm Corp. plans to acquire two Merck & Co. Inc. biopharma units to make a long-term push into biopharmaceutical manufacturing and distribution, possibly leveraging its pharmaceutical subsidiary, Toyama Chemical, Fuijifilm said